The overall goal of the National Policy on HIV/AIDS is to provide for a framework for leadership and coordination of the National multisectoral response to the HIV/AIDS epidemic. This includes formulation, by all sectors, of appropriate interventions which will be effective in preventing transmission of HIV/AIDS and other sexually transmitted infections, protecting and supporting vulnerable groups, mitigating the social and economic impact of HIV/AIDS. It also provides for the framework for strengthening the capacity of institutions, communities and individuals in all sectors to arrest the spread of the epidemic.
Equity and HIV/AIDS
Tanzania National HIV/AIDS Policy
Government of Tanzania, 2001
Tanzania National Multi-sectoral Strategic framework on HIV and AIDS 2003-2007
Tanzania Commission for HIV and AIDS, January 2003
The Strategic Framework is intended to operationalise the National Policy on HIV/AIDS. It provides strategic guidance for developing and implementing HIV/AIDS interventions by various partners. It identifies priority logical set of goals, principles, objectives and strategies to guide multisectoral responses to ensure a strengthened, effective and coordinated national response to the epidemic. It puts strong emphasis on community-based response, that communities are fully empowered and involved in formulating and implementing own responses. It is closely linked with other national development initiatives including Vision 2025, Poverty Reduction Strategy Paper (PRSP) and Medium Term Expenditure Framework (MTEF).
Tanzania: Early marriage puts girls at risk of HIV
IRIN news, 19 September 2006
Data collected by the Tanzania Media Women Association (TAMWA) shows a strong correlation between HIV infection and early school exit, teenage marriage and pregnancy. Tanzanian law is reported in this report to allow girls aged as young as 15 to get married with parental consent.
Tanzania: New roads expose remote areas to HIV - Report
IRIN PLUSnews, 20 September 2006
Rural road construction in Tanzania is opening new markets and providing greater economic opportunities, but can also increase the risk of HIV transmission. "When roads and bridges are built they link low- and high-prevalence areas, such as villages where risk is lower and cities where the prevalence is higher," said a new report by the Tanzania Civil Engineering Contractors Association (TACECA) and the African Medical and Research Foundation (AMREF).
Tanzania: Rising TB cases linked to HIV/AIDS
Integrated Regional Information Networks, 22 March 2007
The number of tuberculosis cases in Tanzania has risen from 39,000 a decade ago to 64,200 in 2005, a trend blamed on high HIV/AIDS prevalence, the Health Minister, David Mwakyusa, said on Thursday. "Research conducted in many parts of the country by the Ministry of Health between 2003 and 2004 established that HIV/AIDS contributes to increased TB cases by about 60 percent," the minister said.
TB failures threaten HIV treatment gains
IRIN PlusNews, 8 August 2008
Tuberculosis (TB) is the biggest killer of people living with HIV in Africa, but only 1% of HIV-positive people accessing treatment were screened for TB in 2006, an oversight that activists say threatens to roll back the gains made in placing more than three million people on life-prolonging anti-retroviral (ARVs) treatment.
Tenofovir gel trial: Results
Centre for the AIDS Programme of Research in South Africa: July 2010
The results of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004 tenofovir gel trial showed a 39% reduction in new HIV infections, and are considered a critical first step to getting an effective HIV prevention method for women. Much more research still needs to be done, CAPRISA cautions. As a follow-up to the CAPRISA 004 tenofovir gel trial, the global microbicide community has yet to define the quickest route to getting tenofovir gel to the public. There was consensus among the community members that confirmatory trials and implementation studies are urgently needed. However, a key challenge is insufficient funding to undertake the critical next steps. The proposed research is expected to cost approximately US$100 million over three years, of which only $58 million has been committed so far.
Tenofovir substitution in Namibia based on an analysis of the antiretroviral dispensing database
Kalemeera F; Mengistu A; Gaeseb J: Journal of Pharmaceutical Policy and Practice 8(14), 2015
In the management of HIV infection, tenofovir (TDF) is preferred to its predecessors based on its safety profile, despite some adverse reactions which warrant its substitution for some patients. This review measured the rate of TDF’s substitution from January 1 2008 to November 30 2011, and compared the gender difference in these rates of substitution using dispensing records from the national antiretroviral dispensing database. No gender difference was observed and the authors indicate that further investigation is required to determine the clinical reasons for TDF’s withdrawal.
Tenofovir trials to start soon in Botswana - despite controversy
Botswana will soon be embarking on the clinical trials of the anti-AIDS drug, tenofovir, despite concerns over how the tests were conducted in Cameroon, Nigeria and Cambodia. The antiretroviral drug, manufactured by US pharmaceutical company Gilead and sold under the brand name, 'Viread', will be tested as a possible prophylactic to prevent people becoming infected with the HI virus.
Testing campaign in Kenya surpasses one million target
Plus News: 24 December 2009
An ambitious, door-to-door voluntary counselling and testing (VCT) exercise launched in November 2009 has resulted in more than 1.5 million Kenyans being tested for HIV, according to a senior government official. 'Our preliminary data show that during the [first] three weeks… [] … we tested 1.5 million people and, as we continue putting our records together, we could go way above this number,' said Nicholas Muraguri, director of the National AIDS and Sexually transmitted infections Control Programme (NASCOP). 'Normally men do not come forward to be tested but this time round we are impressed... Our results show they formed 40% of the total number tested,' he added. 'Those above 50 also turned out in large numbers. Government research shows they are at risk because they too are sexually active.' He noted that the campaign reached out to most at-risk populations such as commercial sex workers through 'moonlight' VCT centres that opened out of regular business hours. The campaign was part of the government's initiative to have at least 80% of Kenyans tested for HIV by the end of 2010.